Larazotide: the celiac peptide that almost made it
Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board
- Larazotide is a small oral peptide designed to tighten the gut lining in celiac disease. It reached a phase 3 trial.
- In trials, it never clearly changed the gut-permeability measure it was designed to fix, and in phase 2b only the lowest dose helped symptoms.
- Its phase 3 trial was stopped in June 2022 after an interim analysis found the effect too small to prove with a feasible number of patients.
- It is not approved. Its story is a warning about 'leaky gut' claims for peptides sold online.
What larazotide was meant to do
Lifelong adherence to a strict gluten-free diet is the cornerstone of treating celiac disease 1, and recurrent symptoms are common despite it; when the phase 2b trial was published in 2015, no approved or proven non-dietary treatment was available 2. Larazotide acetate is a synthetic peptide of eight amino acids, taken by mouth, designed to act on the tight junctions that seal the gaps between intestinal cells 3. A 2021 review describes it as thought to act as a zonulin antagonist, reducing zonulin-driven increases in permeability and rearranging tight-junction proteins, with later work linking it to inhibition of myosin light chain kinase (review) 4. Two of that review's four authors were employed by Innovate Biopharmaceuticals (author affiliations) 4.
The idea: tight-junction disassembly and gut permeability are believed to have an important role in carrying gluten peptides into the gut wall, where they trigger the immune response, so closing the junctions might blunt the reaction to gluten exposure 5.
The early trials: symptoms yes, permeability no
A 2007 proof-of-concept study, a small randomised in-patient safety study run by its first developer, Alba Therapeutics (author affiliation), looked promising: after gluten, intestinal permeability rose 70% on placebo and not at all on larazotide, with fewer gastrointestinal symptoms (randomised trial) 1. The larger trials did not reproduce the permeability effect. In a 2012 gluten-challenge trial of 86 patients, the permeability measure was too variable in the outpatient setting to show an effect, though some lower doses limited worsening of symptoms (randomised trial) 5. In a 2013 trial of 184 patients given 2.7 g of gluten a day for six weeks, the permeability ratio did not differ from placebo; the 1 mg dose limited symptoms, and all doses blunted the rise in an antibody linked to celiac activity (randomised trial) 6.
A 2022 meta-analysis of four randomised trials with 626 patients confirmed the pattern: the lactulose-to-mannitol permeability ratio did not differ from placebo, whether or not patients were exposed to gluten; during gluten challenge, larazotide improved symptom scores and reduced gluten-related diarrhoea, but on a gluten-free diet it did not (meta-analysis) 7.
The permeability test and why it is hard to move
The trials measured gut leakiness with the urinary lactulose-to-mannitol ratio, which the 2013 trial called an experimental biomarker of intestinal permeability 6. The 2012 trial reported that the measure was too variable in the outpatient setting to assess an effect 5, and across four trials it never separated from placebo 7. That leaves two possibilities: either larazotide did not change permeability in people, or the test could not show it. Either way, the trials' positive findings rested on symptom scores and, in 2013, an antibody marker 6 2.
How the phase 2b trial was designed
The 2015 trial used a design meant to reduce noise: a four-week placebo run-in before treatment, 12 weeks of treatment, and a four-week placebo run-out afterwards, with the primary endpoint the average on-treatment score on a celiac gastrointestinal symptom scale 2. It also reported exploratory gains at 0.5 mg, including 31% more improved symptom days 2. Three of its eleven authors were employed by Alba Therapeutics (author affiliations) 2.
The phase 2b puzzle: only the lowest dose worked
The trial that justified phase 3 enrolled 342 adults who had been on a gluten-free diet for at least a year but still had symptoms. They took 0.5, 1 or 2 mg three times a day or placebo for 12 weeks. Only 0.5 mg met the primary endpoint, with fewer symptoms than placebo and 26% fewer symptomatic days; the 1 mg and 2 mg doses were no different from placebo (randomised trial) 2.
The authors themselves called the results mixed 2.
| Trial | Setting | Result |
|---|---|---|
| Proof of concept (2007) | Single doses, gluten challenge | Permeability rose 70% on placebo, not on larazotide; fewer symptoms |
| Phase 2 (2012) | Gluten challenge | Permeability too variable to show an effect; some lower doses limited symptom worsening |
| Phase 2 (2013) | Gluten challenge, 2.7 g a day | Permeability no different from placebo; 1 mg limited symptoms; antibody rise blunted |
| Phase 2b (2015) | 342 adults on a gluten-free diet with symptoms | Only the lowest dose, 0.5 mg, beat placebo; 1 and 2 mg did not |
| Phase 3, CeDLara (2022) | Symptomatic adults on a gluten-free diet | Stopped after interim analysis: too many patients needed to show an effect |
Phase 3: stopped at the interim analysis
Larazotide's phase 3 trial, CeDLara, enrolled adults with celiac disease who still had symptoms on a gluten-free diet. On June 21, 2022, its sponsor announced that a pre-specified interim analysis, run by an independent statistician on roughly the first half of the target enrolment after the 12-week double-blind period, had found that the number of additional patients needed to show a significant difference from placebo was too large to support continuing the trial 8. ClinicalTrials.gov lists the trial (NCT03569007) as terminated, "Trial terminated by Sponsor" 9.
The company said it would look for any subgroup or symptom that might have responded, and that completion of those analyses and discussion with FDA would determine further plans 8. As of October 27, 2026, openFDA's Drugs@FDA had no record of larazotide 10, and our encyclopedia records no approval elsewhere 3.
The zonulin question
Larazotide's story is tied to zonulin: the 2021 review describes it as thought to act as a zonulin antagonist 4, and the 2022 meta-analysis calls it an "anti-zonulin" 7. In 2021, Gut published a letter from celiac immunology researchers in Oslo and Leiden titled 'Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications', challenging the link between larazotide (AT-1001) and the zonulin pathway it was said to target (correspondence) 11.
Larazotide beyond celiac disease
Research on the peptide has continued in other settings. A 2025 phase 2a randomised, double-blind, placebo-controlled trial in 12 children with post-COVID multisystem inflammatory syndrome gave larazotide alongside standard care for three weeks and reported faster resolution of gastrointestinal symptoms and faster clearance of viral spike antigen, with no larazotide-related adverse events (randomised trial) 12. Animal studies have explored collagen-induced arthritis in mice and intestinal ischaemic injury in pigs 4. None of this changes its unapproved status.
Why celiac drug trials are difficult
The sponsor's chief medical officer, announcing the halt, pointed to "the challenges and complexities of the disease and the ability to effectively measure outcomes" 8. The 2012 trial found that 2.4 g of gluten a day was enough to worsen symptoms in the placebo arm 5, so small exposures matter to these trials, and the 2013 trial's authors called their own study exploratory 6.
What it teaches about gut peptides
Larazotide has five published randomised trials and a phase 3 1 5 6 2 12 8. Its lessons apply to any peptide sold for gut healing:
- A plausible mechanism and a promising pilot study are where drugs start, not where they prove themselves 1.
- The marker a drug is designed to fix may not move, even if symptoms seem to 7.
- Results that appear at one dose but not others need a bigger trial before anyone relies on them 2.
- Even a company-funded phase 3 can stop when the effect is too small to prove 8.
Our guide to reading a peptide study explains these patterns, and our KPV vs BPC-157 page sets out the human evidence for those two.
Approved gut peptides, for contrast
Some peptides do have proven gut benefits, for specific conditions. Teduglutide (Gattex) is approved for short bowel syndrome in adults and children aged 1 and over who depend on parenteral support 13, and linaclotide (Linzess) for irritable bowel syndrome with constipation, chronic idiopathic constipation in adults and functional constipation in children aged 2 and over 14. Neither is approved for celiac disease.
Questions to ask about any gut peptide claim
- Has it been tested in people with my condition, in a randomised, placebo-controlled trial?
- Did the marker it is supposed to fix actually change, or only symptom scores?
- Did the benefit hold across doses, or appear at only one?
- Was a larger, later trial run, and did it confirm the early result?
- Is the product an approved medicine, or a research powder making a mechanism claim?
What the gluten-challenge trials were testing
Two of the trials deliberately exposed people with well-controlled celiac disease to a measured daily dose of gluten, 2.4 g in one and 2.7 g in the other, to see whether larazotide could blunt the reaction 5 6. That mimics the accidental exposure many people on a gluten-free diet face. In the 2013 trial, all doses blunted the rise in anti-transglutaminase antibodies even though permeability did not change; the authors described this as reduced gluten-induced immune reactivity 6. The drug was not approved 10.
The bottom line
Larazotide was an attempt to treat celiac disease with a peptide that reached phase 3. Its early symptom signals led to phase 3, but its main biomarker never moved, its phase 2b result rested on one dose, its mechanism was challenged, and its phase 3 stopped when the effect proved too small. It is not approved. A 'leaky gut' peptide with no published randomised trial has less human evidence than larazotide had when its phase 3 stopped.
Frequently asked questions
What is larazotide?
An eight-amino-acid oral peptide designed to tighten intestinal tight junctions in celiac disease. It is not approved.
Why did the larazotide phase 3 trial stop?
In June 2022 an interim analysis found the number of additional patients needed to show a significant difference from placebo was too large to justify continuing.
Did larazotide reduce leaky gut?
In trials, its effect on the lactulose-to-mannitol permeability measure did not differ from placebo, although some doses limited symptoms during gluten challenge.
Is larazotide available?
No. As of October 27, 2026 FDA's Drugs@FDA had no record of it, and its phase 3 trial is listed as terminated.
Is there a drug for celiac disease?
When larazotide's phase 2b trial was published in 2015, no approved or proven non-dietary treatment existed; a strict gluten-free diet is the cornerstone of treatment.
Related on Grey Peptides
Sources
- Paterson, B. M., et al. (2007). The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther, 26(5), 757-66. PMID: 17697209
- Leffler, D. A., et al. (2015). Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology, 148(7), 1311-9.e6. PMID: 25683116
- Grey Peptides encyclopedia entries for larazotide (sequence, status: no Drugs@FDA application, read September 30, 2026; NCT03569007 terminated by the sponsor, record updated July 26, 2022), teduglutide and linaclotide (approved indications). Read October 3, 2026.
- Slifer, Z. M., et al. (2021). Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol, 320(6), G983-G989. PMID: 33881350
- Leffler, D. A., et al. (2012). A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol, 107(10), 1554-62. PMID: 22825365
- Kelly, C. P., et al. (2013). Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther, 37(2), 252-62. PMID: 23163616
- Hoilat, G. J., et al. (2022). Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol, 46(1), 101782. PMID: 34339872
- 9 Meters Biopharma (the developer). 9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation. Press release, June 21, 2022 (Exhibit 99.1 to an SEC filing, EDGAR). Read October 3 and October 27, 2026.
- ClinicalTrials.gov. NCT03569007, Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms (sponsor 9 Meters Biopharma): status Terminated, 'Trial terminated by Sponsor'; last update posted July 26, 2022. Read October 27, 2026. ClinicalTrials.gov
- US FDA. openFDA Drugs@FDA endpoint, searched for larazotide October 27, 2026: no record. Cited without a link.
- Sollid, L. M., et al. (2021). Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications. Gut, 70(11), 2211-2212. PMID: 33443022
- Yonker, L. M., et al. (2025). Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. Sci Transl Med, 17(809), eadu4284. PMID: 40737433
- Takeda. GATTEX (teduglutide) prescribing information, Indications and Usage. DailyMed set 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa, version 20, effective September 5, 2025; read October 27, 2026. DailyMed
- Allergan. LINZESS (linaclotide) prescribing information, Indications and Usage. DailyMed set 09beda19-56d6-4a56-afdc-9a77b70b2ef3, version 40, effective October 9, 2026; read October 27, 2026. DailyMed
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead